| The ICARUS project : study protocol for a randomised controlled trial Investigating aCute heArt failuRe decongestion guided by lung UltraSonography | Trials |  | | 2026 | 26 | 187 |
|
| Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants | Frontiers in pharmacology | | | 2026 | 21 | 37 |
|
| Cytochrome P450 phenotyping using the Geneva cocktail improves metabolic capacity prediction in a hospitalized patient population | British journal of clinical pharmacology |  | | 2025 | 63 | 0 |
|
| Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling | Clinical pharmacokinetics | | | 2025 | 81 | 232 |
|
| Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban | British journal of clinical pharmacology | | | 2025 | 96 | 1 |
|
| Multi-omics correlates of insulin resistance and circadian parameters mapped directly from human serum | European journal of neuroscience | | | 2024 | 96 | 275 |
|
| Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side | CPT: pharmacometrics & systems pharmacology | | | 2023 | 156 | 597 |
|
| Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study | CPT: pharmacometrics & systems pharmacology | | | 2023 | 144 | 532 |
|
| Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial | Clinical and translational science | | | 2022 | 166 | 208 |
|
| Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting | Journal of personalized medicine | | | 2022 | 234 | 454 |
|
| Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities | Clinical pharmacology and therapeutics | | | 2022 | 191 | 405 |
|
| Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients | Acta Physiologica | | | 2021 | 407 | 3 |
|
